By Regulatory Approvals — FDA approves Rhapsido (remibrutinib) for symptomatic dermographism The Clinical Trial Vanguard
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. October 8, 2026.